Reply to “Tolerogenic insulin peptide therapy precipitates type 1 diabetes”

In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Carolin, Weigmann, Benno, von Boehmer, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2017
Materias:
Reply
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501570/
https://www.ncbi.nlm.nih.gov/pubmed/28536240
http://dx.doi.org/10.1084/jem.20170285
Descripción
Sumario:In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3(+) regulatory T cell conversion.

Ejemplares similares